semaglutide cardiovascular benefits New Science Suggests Improves CV Outcomes Beyond Weight Loss Weight loss drug semaglutide benefits
Description
JAMA Network Open, 8 (3), e250186
95% CI, 1.10-1.47), cholecystitis (RR, 1.36
A phase 2 clinical trial published in the New England Journal of Medicine (2023) demonstrated significant body weight reductions in participants with obesity, generating considerable scientific interest
Each medication should be separated to prevent cross-contamination and to allow different temperature monitoring for different stability profiles
Its long-term safety profile is still under investigation
Their average age was 54
